RBC Optimistic on Regeneron Following Lower Sales by Novartis’ Lucentis
Benzinga Adnan Butt added that Lucentis growth in non-wet AMD indications outside the U.S. suggests that there is room for Eyelea to expand as it secures other approvals, including diabetic macular edema (DME). The analyst expects to Eyelea to capture more than … |
Source: Wet Macular Degeneration News From Google News